Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 4Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Lung Neoplasms 1

Interventions

Injections 41Carboplatin 34Cisplatin 24Capecitabine 24Paclitaxel 23Docetaxel 23pembrolizumab 21Oxaliplatin 21Gemcitabine 20Pemetrexed 19Bevacizumab 18Fluorouracil 13Irinotecan 12Cyclophosphamide 12osimertinib 9Nivolumab 8Dexamethasone 8tislelizumab 7Topotecan 7Leucovorin 7Doxorubicin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6regorafenib 6lenvatinib 6fludarabine 6Rituximab 6Cetuximab 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × Pafolacianine × Clear all
NCT07469202 2026-03-13

CYTALUX Dose Extension Study

On Target Laboratories, LLC

Phase 4 Not yet recruiting
106 enrolled
GynecologicThoracic

Lung Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡